According to Markntel Advisors Report, Non-Small Cell Lung Cancer Market is expected to grow at a significant growth rate, and the analysis period is 2022-2027, considering the base year as 2021.Consistent monitoring and evaluating of market dynamics to stay informed and adapt your strategies accordingly. As a market research and consulting firm, we offer market research reports that focus on major parameters including Target Market Identification, Customer Needs and Preferences, Thorough Competitor Analysis, Market Size & Market Analysis, and other major factors. At the end, we do provide meaningful insights and actionable recommendations that inform decision-making and strategy development.

Non-Small Cell Lung Cancer (NSCLC) is the most common & epithelial type of lung cancer that occurs in different forms, viz., Squamous Cell Carcinoma (SCC), Large Cell Carcinoma (LCC), & Adenocarcinoma. Smoking is mainly responsible for NSCLC since smokers are more likely to develop NSCLC. However, it is observed that adenocarcinoma has also occurred in patients with no smoking history.

 

Non-Small Cell Lung Cancer Market Research Report & Summary:

The Global Non-Small Cell Lung Cancer (NSCLC) Market is projected to grow at a CAGR of around 11.2% during the forecast period, i.e., 2022-27.                 

Time Period Captured in the Report:

• Historical Years: 2017-20
• Base Years: 2021
• Forecast Years: 2022-27

Who are the Key Players Operating in the Non-Small Cell Lung Cancer Market?

The top companies of the Non-Small Cell Lung Cancer Market ruling the industry are: 

Allergan (AbbVie), AstraZeneca PLC, Boehringer Ingelheim, Bristol Myers Squibb, Eisai Co., Ltd, Eli Lilly and Company, GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, Other

✅In case you missed it, we are currently revising our reports. Click on the below to get the latest research data with forecast for years 2025 to 2030, including market size, industry trends, and competitive analysis. It wouldn’t take long for the team to deliver the most recent version of the report. 

Access the detailed PDF Sample report – https://www.marknteladvisors.com/query/request-sample/non-small-cell-lung-cancer-market.html

(“Kindly use your official email ID for all correspondence to ensure seamless engagement and access to exclusive benefits, along with prioritized support from our sales team.”)

What is Included in Non-Small Cell Lung Cancer Market Segmentation?

The Non-Small Cell Lung Cancer Market explores the industry by emphasizing the growth parameters and categorizes including geographical segmentation, to offer a comprehensive understanding of the market dynamic.  The further bifurcations are as follows:

• By Diagnosis
  • Blood & Urine Tests
  • Imaging
  • Biopsy
  • Sputum Cytology
  • Bronchoscopy
• By Cancer Type
  • Squamous Cell Carcinoma (SCC)
  • Large Cell Carcinoma (LCC)
  • Adenocarcinoma
• By Treatment
  • Surgery
  • Chemotherapy
  • Immunotherapy
    • Immune Checkpoint Inhibitors
      • PD-1/PD-L1 Inhibitors
      • CTLA-4 Inhibitor
  • Radiation Therapy
    • External Beam Radiation Therapy
    • Brachytherapy (Internal Radiation Therapy)
  • Radiofrequency Ablation (RFA)
  • Targeted Therapy
• By End-User
  • Hospitals
  • Cancer Centers
  • Others (Ambulatory Surgery Centers, etc.)
• By Region
  • North America
  • South America
  • Europe
  • Middle East & Africa
  • Asia-Pacific

 Explore the Complete Non-Small Cell Lung Cancer Market Analysis Report – https://www.marknteladvisors.com/research-library/non-small-cell-lung-cancer-market.html

Market Segmentation

Based on the Cancer Type:

• Squamous Cell Carcinoma (SCC)
• Large Cell Carcinoma (LCC)
• Adenocarcinoma

Of all cancer types, adenocarcinoma is anticipated to dominate the Global Non-Small Cell Lung Cancer (NSCLC) Market with the largest share during 2022-27. It attributes principally to higher cases of adenocarcinoma than other types of NSCLC, i.e., propagating the need for its effective diagnosis & treatment.

Adenocarcinoma generally occurs in the outer region of the lungs, grows slower than other lung cancers, and is more likely to be diagnosed in its early stage. It is seen commonly in females & non-smoker males. Apart from this, the younger generation is among the prominent patients.

Governments of different countries are making active efforts to spread awareness of the availability of diagnosis & treatment and the need to restrain habits like smoking. With rapid developments in medical science, there are various treatments for NSCLC, depending upon the patient’s health condition:

• Surgery: The treatment is one of the prominent therapies performed whenever possible to remove the Adenocarcinoma tumor from the lungs. However, it is done only after determining the tumor location & size and overall health & pulmonary functions of patients.
• Radiation Therapy: In this treatment, high-energy rays are targeted directly at tumor cells to destroy them or curb their growth. These radiations also include external beam radiation therapy to send radiation from outside the body into the affected area. Another method, Brachytherapy, is when the radiation is sent internally by injecting a radioactive substance with a bronchoscope directly into the tumor or near the area. This treatment is also done post-surgery to prevent the possibility of reoccurrence.
• Targeted Therapy: It is an extensively used treatment for patients with adenocarcinoma NSCLC since it less damages the healthy cells than other therapies. Monoclonal antibodies, Tyrosine Kinase Inhibitors (TKIs), and mammalian Target of Rapamycin (mTOR) inhibitors are various Targeted drugs that help destroy specific cancer cells.

Need personalized insights? Click here to customize this report- https://www.marknteladvisors.com/query/request-customization/non-small-cell-lung-cancer-market.html

Why Markntel Advisor Report?

MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.

We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others.

For Further Queries:

Contact Us

MarkNtel Advisors

Email at –sales@marknteladvisors.com

Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh – 201271, India